Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial

Critical Reviews in Oncology/Hematology

Volumn 47, Issue 2, 2003, Pages 171-179

  Lehmann, Jan ^a   Retz, Margitta ^a   Stöckle, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Advanced urothelial cancer; Bladder cancer; Medical resources utilization; Quality of life; Systemic chemotherapy

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; BLADDER CANCER; BLEEDING; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG TOLERABILITY; FEVER; HEALTH CARE UTILIZATION; HEMATURIA; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERFORMANCE; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TOXICITY; VOMITING;

EID: 0043169597     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00080-5     Document Type: Review

References (29)

1. Sternberg C.N., Yagoda A., Scher H.I., et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133:1985;403-407.
2. Loehrer P.J. Sr, Einhorn L.H., Elson P.J., et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10:1992;1066-1073.
3. Saxman S.B., Propert K.J., Einhorn L.H., et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 15:1997;2564-2569.
4. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8:1990;1050-1055.
5. von der Maase H., Hansen S.W., Roberts J.T., et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18:2000;3068-3077.
6. Yates J.W., Chalmer B., McKegney F.P. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 45:1980;2220-2224.
7. Roychowdhury D.F., Hayden A., Liepa A. Health related quality of life (HRQoL) parameters as independent prognostic factors in advanced bladder cancer. Proc. Am. Soc. Clin. Oncol. 20:2001;781.
8. von der Maase H., Andersen L., Crino L., Weinknecht S., Dogliotti L. Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial. Ann. Oncol. 10:1999;1461-1465.
9. Moore M.J., Winquist E.W., Murray N., et al. Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 17:1999;2876-2881.
10. Kaufman D., Raghavan D., Carducci M., et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J. Clin. Oncol. 18:2000;1921-1927.
11. Castellano D., Lianes P., Paz-Ares L., et al. A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer. Ann. Oncol. 9:1998;457-459.
12. Lippert CM, Koser MF. Gemcitabine and cisplatinum in a 21-day schedule in the first-line treatment of locally advanced or metastatic transitional cell carcinoma: preliminary results of a phase II study, Proc Am Soc Clin Oncol 2001:20:abstract 783.
13. Cox D.R., Fitzpatrick R., Fletcher A.E., Gore S.M., Spiegelhalter D.J., Jones D.R. Quality of life assessment: can we keep it simple? J. R. Stat. Soc. 155:1992;353-393.
14. Osoba D., Aaronson N., Zee B., Sprangers M., te Velde A. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The study group on quality of life of the EORTC and the symptom control and quality of life committees of the NCI of Canada Clinical Trials Group. Qual. Life Res. 6:1997;103-108.
15. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J. Natl. Cancer Inst. 85:1993;365-376.
16. Bjordal K., de Graeff A., Fayers P.M., et al. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur. J. Cancer. 36:2000;1796-1807.
17. Glasziou P.P., Simes R.J., Gelber R.D. Quality adjusted survival analysis. Stat. Med. 9:1990;1259-1276.
18. Gelber R.D., Cole B.F., Gelber S., Goldhirsch A. Comparing treatments using quality-adjusted survival: the Q-TWiST method. Am. Stat. 49:1995;161-169.
19. Cole B.F., Gelber R.D., Gelber S., Coates A.S., Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 358:2001;277-286.
20. Mor V., Laliberte L., Morris J.N., Wiemann M. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer. 53:1984;2002-2007.
21. Schaafsma J., Osoba D. The Karnofsky performance status scale re-examined: a cross-validation with the EORTC-C30. Qual. Life Res. 3:1994;413-424.
22. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17:1999;3173-3181.
23. Copley-Merriman C., Corral J., King K., et al. Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer. Lung Cancer. 14:1996;45-61.
24. Oliver E., Killen J., Kiebert G., et al. Treatment pathways, resource use and costs in the management of small cell lung cancer. Thorax. 56:2001;785-790.
25. Hutton J., Brown R., Borowitz M., Abrams K., Rothman M., Shakespeare A. A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics. 9:(Suppl. 2):1996;8-22.
26. Copley-Merriman C., Martin C., Johnson N., Sacristan J.A., Drings P.A., Bosanquet N. Economic value of gemcitabine in non-small cell lung cancer. Semin. Oncol. 23:1996;90-98.
27. Sacristan J.A., Kennedy-Martin T., Rosell R., et al. Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer. Lung Cancer. 28:2000;97-107.
28. Penberthy L., Retchin S.M., McDonald M.K., et al. Predictors of medicare costs in elderly beneficiaries with breast, colorectal, lung, or prostate cancer. Health Care Manage. Sci. 2:1999;149-160.
29. von der Maase H. Gemcitabine-containing regimens in bladder cancer: a new standard of care. Semin. Oncol. 28:2001;1-3.